Condition
    Effectiveness 2/5

    Alpha Lipoic Acid (ALA) for Burning Sensation

    Alpha-lipoic acid (ALA) is one of the few supplements with genuine randomized-trial support for neuropathic symptoms — specifically diabetic peripheral neuropathy, the most common cause of burning feet. The evidence centers on symptom relief (burning, tingling, pain scores) rather than reversing nerve damage, and the strongest data come from intravenous ALA, with oral forms showing smaller, less consistent effects. It does nothing for burning caused by reflux, infection, or skin conditions — the cause of the burning determines everything.

    Overview

    Alpha-lipoic acid (ALA) is one of the few supplements with genuine randomized-trial support for neuropathic symptoms — specifically diabetic peripheral neuropathy, the most common cause of burning feet. The evidence centers on symptom relief (burning, tingling, pain scores) rather than reversing nerve damage, and the strongest data come from intravenous ALA, with oral forms showing smaller, less consistent effects. It does nothing for burning caused by reflux, infection, or skin conditions — the cause of the burning determines everything.

    Verdict

    Mixed evidence

    Reasonable adjunct for diabetic neuropathy symptoms; not a fix, and irrelevant for non-neuropathic burning.

    How It Works

    ALA is a mitochondrial antioxidant that regenerates other antioxidants (vitamins C and E, glutathione), reduces oxidative stress implicated in diabetic nerve injury, and improves endoneurial blood flow and nerve conduction velocity. In diabetes, chronic hyperglycemia generates oxidative stress that damages small nerve fibers; ALA's proposed benefit is dampening this oxidative pathway and improving nitric-oxide-mediated microcirculation to nerves.

    Dosing & Protocol

    Typical dose

    Recommended dose
    600–1,800 mg/day (trials: 600 mg 1–3× daily)
    Expected timeframe
    4–8 weeks for symptom-score changes in responsive patients

    Protocol

    notes
    R-ALA form is more bioavailable; standard racemic ALA is what most trials used
    dosage
    600 mg once to three times daily on an empty stomach (food cuts absorption ~30%)
    duration
    8–12 week minimum trial; IV protocols in studies ran 3 weeks

    Evidence

    What the studies say

    The SYDNEY and NATHAN trial programs found IV ALA (600 mg/day) significantly improved neuropathic symptom scores over placebo over 3 weeks; oral ALA trials (600–1,800 mg/day for 4–6 months) showed modest improvements in symptom scores but little effect on objective nerve conduction. A 2012 meta-analysis of 4 trials (~1,200 patients) confirmed symptom-score benefits concentrated with IV dosing. No trial demonstrates reversal of established nerve damage, and evidence is weak outside diabetic neuropathy.

    Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial

    Score: 8/10
    2006
    rct
    n=181

    Ziegler D, Ametov A, Barinov A +3 more

    Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.

    View source

    Alpha-lipoic acid for diabetic peripheral neuropathy: a meta-analysis of randomized controlled trials

    Score: 7/10
    2012
    meta_analysis
    n=653

    Han T, Bai J, Liu W

    Alpha-lipoic acid improved neuropathic symptom scores including burning pain.

    View source

    Alpha lipoic acid in burning mouth syndrome - a randomized double-blind placebo-controlled trial

    Score: 7/10
    2009
    rct
    n=38

    Cavalcanti DR, da Silveira FR

    Alpha-lipoic acid did not outperform placebo in burning mouth syndrome.

    View source

    Safety

    Caveats

    ALA lowers blood sugar — diabetics on medication need glucose monitoring to avoid hypoglycemia. Rare reports of insulin autoimmune syndrome. High doses can cause nausea and reflux. It does not substitute for glucose control, which is what actually slows neuropathy. Never use as a reason to skip a neuropathy workup — B12 deficiency and other causes need direct treatment.

    Less likely to help if

    People with long-standing severe neuropathy (little nerve function left to protect), non-diabetic neuropathy causes, and those with poor glycemic control — symptom effects are modest at best. If 12 weeks at 600–1,800 mg/day produces no change, discontinue.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.